Thyroid Eye Disease (TED), also called Graves’ ophthalmopathy, isn’t just an eye problem-it’s an autoimmune attack on the tissues behind your eyes. It happens when your immune system mistakes the fat and muscle around your eyes for a threat and starts swelling them up. This can push your eyeballs forward, cause double vision, make your eyes feel gritty or painfully dry, and even threaten your sight if left untreated. About 16 out of every 100,000 people develop it each year, and women are far more likely to be affected than men. If you have Graves’ disease, your risk jumps to nearly half. But TED can also show up in people with normal or low thyroid function, which makes it easy to miss.
What Does Thyroid Eye Disease Actually Feel Like?
Most people don’t realize how much their eyes are changing until they can’t look straight ahead anymore. The most common symptoms aren’t subtle. You might notice your eyes feel like they’re full of sand-78% of patients report a gritty sensation. Light sensitivity hits 65%, and 52% feel pain when they move their eyes. Redness isn’t just from tiredness; it’s swelling in the conjunctiva. Dry eyes? That’s 61%. Excessive tearing? 39%. Puffy eyelids? 44%. And then there’s the bulging: 31% have noticeable proptosis, where the eyeball sticks out so far it doesn’t close properly.
Double vision is one of the scariest signs. It happens because the eye muscles get inflamed and stiff, making them move out of sync. About 28% of people with TED develop diplopia. In 89% of cases, both eyes are affected, but some only get it in one eye. The severity is measured by the Clinical Activity Score (CAS). If your score is 3 or higher, your disease is still active and inflamed. That’s when treatment needs to start-fast.
Why Do Your Eyes Swell Like This?
It all starts with antibodies. In Graves’ disease, your body makes TSH receptor antibodies (TRAb). These usually target the thyroid, but they also latch onto fibroblasts in the tissue behind your eyes. That triggers inflammation, fat growth, and fluid buildup. The muscles that move your eyes swell up, especially the inferior and medial rectus muscles-85% and 75% of cases, respectively. This pressure pushes the eyeball forward, stretches the optic nerve, and can block blood flow.
Smoking is the biggest risk factor. People who smoke are more than 7.7 times as likely to get TED than non-smokers. Women over 40 are at highest risk. High TRAb levels (>15 IU/L) mean you’re more likely to develop severe eye symptoms. Even treatment for your thyroid can make it worse. Radioactive iodine therapy, if given without steroids, can double or even triple your TED risk.
Steroids: The First-Line Defense
When TED is active, doctors reach for steroids. They don’t cure the disease, but they calm the inflammation. The gold standard is intravenous methylprednisolone. You get a 500 mg dose once a week for six weeks, then 250 mg for another six weeks. This works for 60-70% of people with moderate-to-severe TED. It reduces swelling, eases pain, and improves double vision. It’s better than oral steroids because it hits the eye tissue directly and avoids some gut-related side effects.
Oral prednisone is still used, especially for milder cases. But it’s a double-edged sword. You might gain 8.2 kg on average. 18% develop glucose intolerance, and bone density drops. About 25-30% of people relapse after stopping it. The European guidelines say you shouldn’t go over 4.5-5.0 grams total IV steroid dose. Liver toxicity happens in 2.3% of cases, so monitoring is key.
Biologics: A Game-Changer in TED Treatment
Before 2020, steroids were the only real option. Then teprotumumab (Tepezza®) changed everything. It’s not a general immune suppressor-it targets the root cause. Teprotumumab blocks the IGF-1 receptor, which is overactive in TED orbital tissue. In the OPTIC trial, 71% of patients saw their eyeballs retreat by at least 2 mm, compared to just 20% on placebo. Double vision improved in 59% of those on teprotumumab versus 26% on placebo. The difference was dramatic.
The treatment is eight infusions over 22 weeks. The first dose is 10 mg/kg, then 20 mg/kg every three weeks. It costs around $360,000 in the U.S., and insurance denials are common. About 42% of patients wait an average of 47 days just to get approval. Some patients report muscle spasms, hearing changes, or spikes in blood sugar. Still, 74% of patients say they’re more satisfied with biologics than steroids because they don’t gain weight or develop prediabetes.
What About Other Biologics?
Teprotumumab isn’t the only one. Satralizumab (Enspryng®), an anti-IL-6 antibody, got FDA approval in 2023. It’s given as a monthly under-the-skin shot, which is easier than IV infusions. In trials, it helped 54% of patients reduce proptosis. Rituximab and tocilizumab are being studied too, but the data isn’t as strong. Right now, teprotumumab is the only one with solid, large-scale evidence.
What If Steroids and Biologics Don’t Work?
Some patients still need surgery. Orbital decompression removes bone behind the eye to create space for the swollen tissue. It reduces bulging by 2-5 mm, but it can make double vision worse in 15% of cases. Strabismus surgery fixes misaligned eyes, and eyelid surgery corrects retraction. These are done only after the disease has been inactive for at least six months. Prisms in glasses help with double vision, but only if the muscle imbalance is under 15 prism diopters.
What Can You Do Right Now?
If you have mild TED, start with simple steps: preservative-free artificial tears, sleeping with your head elevated, and wearing sunglasses. Selenium supplements (200 mcg daily) may help a little-23% improvement in quality of life in one major review. But don’t rely on them alone. If your symptoms are getting worse, see an endocrinologist and ophthalmologist together. Don’t wait. The earlier you treat the active phase, the less likely you are to need surgery later.
What’s on the Horizon?
The TED treatment market is exploding. Tepezza made $2.1 billion in sales in 2022. A biosimilar is coming by 2025, which could cut costs by 30-40%. Researchers are testing combinations-like teprotumumab plus selenium-and early results show 82% response rates. Genetic testing might soon tell you if you’re at high risk before you even develop symptoms. The goal is to stop TED before it starts, not just treat it after it damages your eyes.
Can thyroid eye disease go away on its own?
Yes, but only in mild cases and only after the active phase ends-usually after 6 to 24 months. The inflammation will calm down, but the damage-like bulging eyes or muscle scarring-often stays. That’s why early treatment matters. Waiting to see if it gets better can lead to permanent changes that require surgery.
Are steroids the only treatment for thyroid eye disease?
No. While steroids were the only proven treatment for decades, teprotumumab is now the first-line option for moderate-to-severe active TED. It works better and has fewer long-term side effects. Other biologics like satralizumab are also emerging. Steroids are still used, especially when biologics aren’t available, but they’re no longer the only choice.
Does quitting smoking help with thyroid eye disease?
Absolutely. Smoking doesn’t just increase your risk-it makes the disease worse and harder to treat. People who quit smoking after diagnosis have less inflammation, better response to steroids and biologics, and lower chances of needing surgery. It’s one of the most effective things you can do, even if you’ve had TED for years.
Why is teprotumumab so expensive?
Teprotumumab is a targeted biologic developed by Horizon Therapeutics (now owned by Amgen). Its development cost billions, and it’s the only FDA-approved drug for TED, giving it a monopoly. Insurance companies often deny coverage, and even with insurance, patients can pay thousands per infusion. A biosimilar is expected by 2025, which should lower prices significantly.
Can I get TED even if my thyroid levels are normal?
Yes. About 10-15% of TED cases happen in people with normal thyroid function (euthyroid) or even hypothyroidism. The immune attack on the eye tissues is separate from thyroid hormone levels. That’s why doctors check for TRAb antibodies and do orbital imaging-even if your thyroid tests look fine.
